This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Gastric Motor Function Measurement in Dyspepsia and Normal Subjects

This study has been completed.
Information provided by:
Mayo Clinic Identifier:
First received: February 24, 2006
Last updated: May 20, 2011
Last verified: May 2011
This study is being done to measure the functions of the stomach after eating a meal and to develop a new method that will simultaneously measure both gastric emptying and the relaxation of the stomach after a meal using nuclear medicine testing. This would make the testing more convenient for patients and will also offer better understanding of these two gastric functions.

Condition Intervention
Dyspepsia Behavioral: Gastric Motor Function Measurement

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Simultaneous Gastric Motor Function Measurement in Dyspepsia And Normal Subjects Ingesting a Solid-Liquid Meal

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Fasting and postprandial gastric volumes (Gastric accommodation)

Secondary Outcome Measures:
  • T1/2 of gastric emptying of solid
  • Maximum tolerated volume
  • Individual postprandial symptom scores

Enrollment: 30
Study Start Date: January 2006
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

Dyspeptic Subjects:

  • Recurrent episodes of upper abdominal pain or discomfort including early satiety, fullness, bloating, or nausea for at least 3 months in the prior year.
  • A baseline impaired satiety test (maximum tolerated volume 25% of normal or 1000cc).
  • No evidence on esophagogastroduodenoscopy of erosions, peptic ulcer, pyloric obstruction, esophagitis or malignancy in the prior 3 years.

All Subjects:

  • No history suggestive of small bowel obstruction.

Exclusion criteria

  • No structural or metabolic diseases/conditions that affect the gastrointestinal system.
  • Unable to stop medications 48 hours prior to the study that:

    • Alter GI transit including laxatives, magnesium or aluminum-containing antacids, prokinetics, erythromycin, narcotics, anticholinergics, tricyclic antidepressants, SSRI and newer antidepressants.
    • Analgesic drugs including opiates, NSAID, COX 2 inhibitors
    • Systemic antifungal drugs
    • Carbamazepine, glucocorticoids, phenobarbital, phenytoin, rifampin, but also grapefruit juice.
    • Benzodiazepines NOTE: Low stable doses of thyroid replacement, estrogen replacement, low dose aspirin for cardioprotection and birth control pills or depot injections are permissible.
  • Female subjects who are pregnant or breast feeding.
  • Significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric, or other disease that interfere with the objectives of the study.
  • Subjects who have participated in another clinical study within the past 30 days.
  • Previous gastric or intestinal surgery (except appendectomy , cholecystectomy or hysterectomy).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00296582

United States, Arizona
Mayo Clinic
Scottsdale, Arizona, United States, 85259
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: H. Jae Kim, M.D. Mayo Clinic
  More Information

Responsible Party: Hack Jae Kim, M.D., Mayo Clinic Identifier: NCT00296582     History of Changes
Other Study ID Numbers: 65-06
Study First Received: February 24, 2006
Last Updated: May 20, 2011

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms processed this record on August 18, 2017